A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

LabMinds Secures Financing to Boost Commercial Growth of The REVO® Robotic System

LabMinds, Inc., an award-winning robotics company in life sciences, today announced it has closed a fully subscribed funding round from a mix of private and strategic investors.

The round was closed at a 20% higher share price than the funding round completed in 2019, reflecting the substantial progress the company has made. This funding will help drive the commercialization of its automation system as well as facilitate the expansion of LabMinds’ product portfolio.

“We are pleased to announce the completion of a fully subscribed funding round,” said Jeff Caputo, President & CEO of LabMinds, Inc. “We appreciate the support and excitement by our existing and new investors. Not only do they recognize the large market opportunity for this innovative technology, they also acknowledge the considerable value it brings to the drug development process especially during these challenging times. Our REVO automation system ensures reliability, traceability and consistency which are critical for solution preparation.”

“Our team at LabMinds continues to build traction within the bio-pharma world, with multiple large customers moving toward using The REVO platform to standardize processes,” said John Kawola, Chairman of the Board, LabMinds. “Automation in solution preparation has been lacking. The REVO fills this gap and accelerates drug development while saving time and money for our customers. The Board and Investors are excited to continue to support the Company’s growth.”

LabMinds’ customers have been taking full advantage of The REVO and its automation capabilities to help with rapid COVID-19 drug discovery and development as well as facilitate remote operations.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy